Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · Real-Time Price · USD
2.985
-0.075 (-2.45%)
At close: May 12, 2025, 4:00 PM
3.020
+0.035 (1.17%)
After-hours: May 12, 2025, 4:49 PM EDT
Organogenesis Holdings Revenue
Organogenesis Holdings had revenue of $86.69M in the quarter ending March 31, 2025, a decrease of -21.17%. This brings the company's revenue in the last twelve months to $458.76M, up 5.35% year-over-year. In the year 2024, Organogenesis Holdings had annual revenue of $482.04M with 11.29% growth.
Revenue (ttm)
$458.76M
Revenue Growth
+5.35%
P/S Ratio
0.85
Revenue / Employee
$527,917
Employees
869
Market Cap
378.66M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 482.04M | 48.90M | 11.29% |
Dec 31, 2023 | 433.14M | -17.75M | -3.94% |
Dec 31, 2022 | 450.89M | -16.47M | -3.52% |
Dec 31, 2021 | 467.36M | 129.06M | 38.15% |
Dec 31, 2020 | 338.30M | 77.32M | 29.63% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ORGO News
- 1 day ago - Organogenesis Holdings Inc. (ORGO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness - GlobeNewsWire
- 5 weeks ago - Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025 - GlobeNewsWire
- 2 months ago - Organogenesis Holdings Inc. (ORGO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025 - GlobeNewsWire
- 6 months ago - Organogenesis Expands Manufacturing Capacity to Support Future Growth - GlobeNewsWire